Heron Therapeutics (HRTX) Total Liabilities (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Total Liabilities came in at $237.1 million in Q1 2026, down 10.27% YoY from $264.2 million in Q1 2025, and down 1.85% on a QoQ basis from $241.5 million in Q4 2025.
Heron Therapeutics (HRTX) Total Liabilities (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Total Liabilities data on file, last reported at $237.1 million in Q1 2026.
- Quarterly Total Liabilities fell 10.27% year-over-year to $237.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.1 million (down 10.27% YoY) and the FY2025 annual result came in at $241.5 million, down 9.47% from the prior year.
- Total Liabilities eased to $237.1 million in Q1 2026, from $241.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $266.8 million in Q4 2024 to a low of $232.3 million in Q1 2023.
- A 5-year average of $250.6 million and a median of $251.7 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 117.74% — and 2026, when it declined 10.27%.
- Tracing HRTX's Total Liabilities over 5 years: stood at $237.4 million in 2022, then increased by 8.05% to $256.5 million in 2023, then increased by 4.02% to $266.8 million in 2024, then decreased by 9.47% to $241.5 million in 2025, then slipped by 1.85% to $237.1 million in 2026.
- The last three Total Liabilities figures came in at $237.1 million (Q1 2026), $241.5 million (Q4 2025), and $234.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 245.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 245.35 Mn |
| Mar 31, 2026 | 237.08 Mn |
| Dec 31, 2025 | 241.54 Mn |
| Sep 30, 2025 | 234.07 Mn |
| Jun 30, 2025 | 259.35 Mn |
| Mar 31, 2025 | 264.21 Mn |
| Dec 31, 2024 | 266.80 Mn |
| Sep 30, 2024 | 260.78 Mn |
| Jun 30, 2024 | 256.08 Mn |
| Mar 31, 2024 | 251.65 Mn |
| Dec 31, 2023 | 256.48 Mn |
| Sep 30, 2023 | 256.99 Mn |
| Jun 30, 2023 | 240.51 Mn |
| Mar 31, 2023 | 232.31 Mn |
| Dec 31, 2022 | 237.38 Mn |
| Sep 30, 2022 | 249.50 Mn |
| Jun 30, 2022 | 265.70 Mn |
| Mar 31, 2022 | 249.77 Mn |
| Dec 31, 2021 | 228.14 Mn |
| Sep 30, 2021 | 233.55 Mn |